ClinicalTrials.gg
CompletedNCT01703091Updated Sep 30, 2019Results posted

A Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer

A Phase 2 interventional study of Ramucirumab and Placebo in Non-small Cell Lung Cancer Metastatic, sponsored by Eli Lilly and Company. Completed at 15 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2019-09-30.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
197
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing ramucirumab in Carcinoma, Non-Small-Cell Lung — 2 open to participants now, 9 under way, 2 of them phase 3. Ramucirumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
5th of 24
197 · median 74
Started
2012
the only one that year
Phase 2
14 of 24
1 open now
Registered
4th of 24
by date
Lead sponsor
10 of 24
Eli Lilly and Company

Among the 24 studies testing ramucirumab in Carcinoma, Non-Small-Cell Lung, this one is the 5th largest by enrollment, is the only one that started in 2012, is one of 14 in phase 2, and was the 4th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

2 of the 24 studies testing ramucirumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About ramucirumab

Ramucirumab: first FDA approval 2014 (CYRAMZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing ramucirumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effects of ramucirumab in combination with docetaxel in participants with Stage IV non-small cell lung cancer who have had disease progression during or after one prior first-line platinum-based chemotherapy with or without maintenance therapy for advanced/metastatic disease.

03

Conditions studied

  • Non-small Cell Lung Cancer Metastatic
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Non-Small Cell Lung Cancer disease
  • Clinical stage IV or recurrent disease
  • One prior platinum-based chemotherapy regimen with or without maintenance therapy
  • For Non-Small Cell Lung Cancer (NSCLC) tumors other than squamous cell histology, the epidermal growth factor receptor (EGFR) mutation status is known prior to randomization
  • For participants with activating epidermal growth factor receptor (EGFR) mutation only, prior epidermal growth factor receptor- tyrosine kinase inhibitor (EGFR-TKI) monotherapy (only one regimen in the setting of single use) should be utilized
  • (ECOG) Performance Status (PS) 0 or 1
  • as defined by (RECIST) version RECIST version 1.1
  • Adequate organ function
  • Estimated of at least 3 months.

Exclusion criteria

Exclusion Criteria:

  • Have undergone major surgery within 28 days prior to randomization or have planned major surgery during study treatment
  • Receiving concurrent treatment with other anticancer therapy
  • Central nervous system disease other than stable and treated
  • Has major blood vessel invasion or encasement by cancer
  • Has intratumor cavitation
  • Has a history of uncontrolled thrombotic disorder
  • Is receiving therapeutic anticoagulation with drugs
  • Is receiving chronic therapy with nonsteroidal anti-inflammatory drugs
  • Has a history of hemoptysis within 2 months prior to randomization
  • Has congestive heart failure
  • Has experienced any arterial thromboembolic event
  • Has uncontrolled arterial hypertension
  • Has had a serious or nonhealing wound or, ulcer
  • Has significant existing conditions
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
197 participants (actual)

Study arms

  • Experimental
    Ramucirumab plus Docetaxel

    Ramucirumab 10 milligram per kilogram (mg/kg) on Day 1 of every 21 day cycle, administered as an intravenous (IV) infusion over approximately 60 minutes. Docetaxel 60 milligram per square meter (mg/m2) on Day 1 of every 21 day cycle, administered as an IV infusion over approximately 60 minutes.

    Drug: Ramucirumab · Drug: Docetaxel

  • Placebo comparator
    Placebo plus Docetaxel

    Placebo (administered at a volume equivalent to a dose of milligram per kilogram (mg/kg)) on Day 1 of every 21 day cycle, administered as an IV infusion over approximately 60 minutes. Docetaxel 60 mg/m2 on Day 1 of every 21 day cycle, administered as an IV infusion over approximately 60 minutes.

    Drug: Placebo · Drug: Docetaxel

Interventions

  • Administered IV

    Also known as: LY 3009806, IMC-1121B, Cyramza®

  • DrugPlacebo

    Administered IV

  • Administered IV

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    PFS was defined as the time from baseline until measured progressive disease (PD) or death from any cause, whichever is first. According to Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1), PD was at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. In addition to the 20% relative increase, the sum must have also demonstrated an absolute increase of at least 5 millimeters (mm). The appearance of 1 or more new lesions and/or unequivocal progression of existing nontarget lesions was also considered progression. Participants without objectively determined PD, who were alive at the end of the follow-up period (or lost to follow-up), were censored on the date of the participant's last complete radiographic tumor assessment; if no baseline or post-baseline radiologic assessment was available, the participant was censored at the date of randomization.

    Time frame: Baseline to Measured Progressive Disease or Death from Any Cause (Up to 21 Months)

Secondary outcomes

  1. Overall Survival (OS)

    OS was defined as time from baseline to the date of death from any cause. Participants who were alive at the end of the follow-up period (or lost to follow-up) were censored on the last date the participant was known to be alive.

    Time frame: Baseline to Death from Any Cause (Up to 28 Months)

  2. Percentage of Participants Who Achieved Best Overall Tumor Response of Complete Response (CR) or Partial Response (PR) [Objective Tumor Response Rate (ORR)]

    Participants achieved an objective response if they had a best overall response of complete response (CR) or partial response (PR). According to RECIST v1.1, CR was the disappearance of all non-nodal target lesions, with the short axes of any target lymph node reduced to \<10 mm, the disappearance of all nontarget lesions, and the normalization of tumor marker levels (if tumor markers were initially above the upper limit of normal \[ULN\]); PR was defined as at least a 30% decrease in the sum of the diameters of target lesions (including the short axes of any target lymph node), taking as reference the baseline sum diameter. The percentage of participants who achieved an objective response equals (number of participants with CR or PR)/(number of participants assessed)\*100.

    Time frame: Baseline to Measured Progressive Disease or Participant Stops Study (Up to 97 Weeks)

  3. Percentage of Participants Who Achieved Best Overall Disease Response of CR, PR or Stable Disease (SD) [Disease Control Rate (DCR)]

    Participants achieved disease control if they had a best overall response of PR, CR or SD. According to RECIST v1.1, CR was the disappearance of all non-nodal target lesions, with the short axes of any target lymph node reduced to \<10 mm, the disappearance of all nontarget lesions, and the normalization of tumor marker levels (if tumor markers were initially above the upper limit of normal \[ULN\]); PR was defined as at least a 30% decrease in the sum of the diameters of target lesions (including the short axes of any target lymph node), taking as reference the baseline sum diameter. SD was neither sufficient shrinkage to qualify as PR nor sufficient increase to qualify as PD, taking as reference the smallest sum diameter since treatment started. The percentage of participants who achieved disease control equals (number of participants with CR, PR, or SD)/(number of participants assessed)\*100.

    Time frame: Baseline to Measured Progressive Disease or Participant Stopped Study (Up to 97 Weeks)

  4. Change From Baseline in European Quality of Life Questionnaire - 5 Dimension (EQ-5D) Index Score

    The EQ-5D is a quality-of-life instrument which allowed participants to rate their health state in 5 health domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression using a scale from 1 to 3 (no problem, some problems, and extreme problems, respectively). These combinations of attributes were converted into a weighted Health State Index score according to a United Kingdom population-based algorithm; the possible values for the Health State Index score ranged from -0.59 (severe problems in all 5 dimensions) to 1.0 (no problem in any dimension).

    Time frame: Baseline, Day 21 Each Cycle (Cycle = 21 Days) and 30-Day Follow Up (Up to 97 Weeks)

  5. Change From Baseline in Lung Cancer Symptom Scale (LCSS)

    The participant-reported LCSS was a 9-item questionnaire. Six items were symptom-specific measures for lung cancer (loss of appetite, fatigue, cough, dyspnea, hemoptysis, and pain), and 3 summation items described total symptomatic distress, interference with activity level, and global quality of life. Participant responses to each item were measured using a visual analog scale (VAS) from 0 (best outcome) to 100 (worst outcome). The Average Symptom Burden Index (ASBI) was the mean of the 6 symptom-specific items in the LCSS. The Total LCSS was the mean of all 9 LCSS items. Maximum improvement in LCSS scores, ASBI, and Total LCSS score was the largest decrease from baseline for each variable, which was the smallest (most negative or smallest positive) non-missing value among all change from baseline values for each variable.

    Time frame: Baseline to Measured Progressive Disease or Participant Stopped Study (up to 97 weeks)

07

Results

Posted Jan 20, 2016

Participant flow

Participant flow — Overall Study
MilestoneRamucirumab Plus DocetaxelPlacebo Plus Docetaxel
Started9899
Received at least one dose of study drug9498
Completed8995
Not completed94
Withdrew: Adverse event53
Withdrew: Physician decision21
Withdrew: Withdrawal by subject10
Withdrew: Sponsor decision10

Outcome measures

PrimaryProgression-Free Survival (PFS)

PFS was defined as the time from baseline until measured progressive disease (PD) or death from any cause, whichever is first. According to Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1), PD was at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. In addition to the 20% relative increase, the sum must have also demonstrated an absolute increase of at least 5 millimeters (mm). The appearance of 1 or more new lesions and/or unequivocal progression of existing nontarget lesions was also considered progression. Participants without objectively determined PD, who were alive at the end of the follow-up period (or lost to follow-up), were censored on the date of the participant's last complete radiographic tumor assessment; if no baseline or post-baseline radiologic assessment was available, the participant was censored at the date of randomization.

Time frame:
Baseline to Measured Progressive Disease or Death from Any Cause (Up to 21 Months)
Reported as:
Median · Months
Progression-Free Survival (PFS)
MonthsRamucirumab + DocetaxelPlacebo + Docetaxel
Progression-Free Survival (PFS)5.22 (3.52 to 6.97)4.21 (2.83 to 5.62)
SecondaryOverall Survival (OS)

OS was defined as time from baseline to the date of death from any cause. Participants who were alive at the end of the follow-up period (or lost to follow-up) were censored on the last date the participant was known to be alive.

Time frame:
Baseline to Death from Any Cause (Up to 28 Months)
Reported as:
Median · Months
Overall Survival (OS)
MonthsRamucirumab + DocetaxelPlacebo + Docetaxel
Overall Survival (OS)15.15 (12.45 to 26.55)14.65 (11.93 to 24.44)
SecondaryPercentage of Participants Who Achieved Best Overall Tumor Response of Complete Response (CR) or Partial Response (PR) [Objective Tumor Response Rate (ORR)]

Participants achieved an objective response if they had a best overall response of complete response (CR) or partial response (PR). According to RECIST v1.1, CR was the disappearance of all non-nodal target lesions, with the short axes of any target lymph node reduced to \<10 mm, the disappearance of all nontarget lesions, and the normalization of tumor marker levels (if tumor markers were initially above the upper limit of normal \[ULN\]); PR was defined as at least a 30% decrease in the sum of the diameters of target lesions (including the short axes of any target lymph node), taking as reference the baseline sum diameter. The percentage of participants who achieved an objective response equals (number of participants with CR or PR)/(number of participants assessed)\*100.

Time frame:
Baseline to Measured Progressive Disease or Participant Stops Study (Up to 97 Weeks)
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved Best Overall Tumor Response of Complete Response (CR) or Partial Response (PR) [Objective Tumor Response Rate (ORR)]
Percentage of ParticipantsRamucirumab + DocetaxelPlacebo + Docetaxel
Percentage of Participants Who Achieved Best Overall Tumor Response of Complete Response (CR) or Partial Response (PR) [Objective Tumor Response Rate (ORR)]28.9 (19.1 to 40.5)18.5 (10.8 to 28.7)
SecondaryPercentage of Participants Who Achieved Best Overall Disease Response of CR, PR or Stable Disease (SD) [Disease Control Rate (DCR)]

Participants achieved disease control if they had a best overall response of PR, CR or SD. According to RECIST v1.1, CR was the disappearance of all non-nodal target lesions, with the short axes of any target lymph node reduced to \<10 mm, the disappearance of all nontarget lesions, and the normalization of tumor marker levels (if tumor markers were initially above the upper limit of normal \[ULN\]); PR was defined as at least a 30% decrease in the sum of the diameters of target lesions (including the short axes of any target lymph node), taking as reference the baseline sum diameter. SD was neither sufficient shrinkage to qualify as PR nor sufficient increase to qualify as PD, taking as reference the smallest sum diameter since treatment started. The percentage of participants who achieved disease control equals (number of participants with CR, PR, or SD)/(number of participants assessed)\*100.

Time frame:
Baseline to Measured Progressive Disease or Participant Stopped Study (Up to 97 Weeks)
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved Best Overall Disease Response of CR, PR or Stable Disease (SD) [Disease Control Rate (DCR)]
Percentage of ParticipantsRamucirumab + DocetaxelPlacebo + Docetaxel
Percentage of Participants Who Achieved Best Overall Disease Response of CR, PR or Stable Disease (SD) [Disease Control Rate (DCR)]78.9 (68.1 to 87.5)70.4 (59.2 to 80.0)
SecondaryChange From Baseline in European Quality of Life Questionnaire - 5 Dimension (EQ-5D) Index Score

The EQ-5D is a quality-of-life instrument which allowed participants to rate their health state in 5 health domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression using a scale from 1 to 3 (no problem, some problems, and extreme problems, respectively). These combinations of attributes were converted into a weighted Health State Index score according to a United Kingdom population-based algorithm; the possible values for the Health State Index score ranged from -0.59 (severe problems in all 5 dimensions) to 1.0 (no problem in any dimension).

Time frame:
Baseline, Day 21 Each Cycle (Cycle = 21 Days) and 30-Day Follow Up (Up to 97 Weeks)
Reported as:
Mean · Units on a Scale
Change From Baseline in European Quality of Life Questionnaire - 5 Dimension (EQ-5D) Index Score
Units on a ScaleRamucirumab + DocetaxelPlacebo + Docetaxel
Cycle 1 (n = 69, 77)-0.024 ± 0.1928-0.007 ± 0.1918
Cycle 2 (n = 62, 66)-0.021 ± 0.21900.006 ± 0.1961
Cycle 3 (n = 48, 53)-0.010 ± 0.2324-0.005 ± 0.1891
Cycle 4 (n = 40, 48)0.015 ± 0.1683-0.026 ± 0.1610
Cycle 5 (n = 32, 40)0.000 ± 0.2280-0.012 ± 0.1433
Cycle 6 (n = 28, 36)0.035 ± 0.1741-0.005 ± 0.1409
Cycle 7 (n = 25 ,31)0.002 ± 0.1857-0.039 ± 0.1282
Cycle 8 (n = 23, 30)-0.053 ± 0.1750-0.071 ± 0.1800
30-Day Follow Up (n= 56, 70)-0.102 ± 0.2209-0.132 ± 0.3344
SecondaryChange From Baseline in Lung Cancer Symptom Scale (LCSS)

The participant-reported LCSS was a 9-item questionnaire. Six items were symptom-specific measures for lung cancer (loss of appetite, fatigue, cough, dyspnea, hemoptysis, and pain), and 3 summation items described total symptomatic distress, interference with activity level, and global quality of life. Participant responses to each item were measured using a visual analog scale (VAS) from 0 (best outcome) to 100 (worst outcome). The Average Symptom Burden Index (ASBI) was the mean of the 6 symptom-specific items in the LCSS. The Total LCSS was the mean of all 9 LCSS items. Maximum improvement in LCSS scores, ASBI, and Total LCSS score was the largest decrease from baseline for each variable, which was the smallest (most negative or smallest positive) non-missing value among all change from baseline values for each variable.

Time frame:
Baseline to Measured Progressive Disease or Participant Stopped Study (up to 97 weeks)
Reported as:
Mean · Millimeter
Change From Baseline in Lung Cancer Symptom Scale (LCSS)
MillimeterRamucirumab + DocetaxelPlacebo + Docetaxel
Loss of Appetite (n=73, 79)-12.5 ± 26.23-16.2 ± 21.45
Fatigue (n=73, 80)-4.9 ± 25.38-7.8 ± 23.59
Cough (n=73, 80)-4.4 ± 23.10-18.3 ± 23.83
Dyspnea (n=73, 80)-4.7 ± 23.09-8.7 ± 20.16
Hemoptysis (n=73, 80)-1.2 ± 12.83-3.7 ± 17.25
Pain (n=73, 80)-9.6 ± 23.66-9.0 ± 21.52
Overall Symptoms (n=73, 80)-7.1 ± 26.10-11.5 ± 19.83
Interference with Activity Level (n=73, 80)-8.4 ± 25.84-11.9 ± 21.98
Quality of Life (n=73, 80)-11.7 ± 28.06-12.7 ± 21.06
ASBI (n=73, 79)-2.82 ± 14.93-6.93 ± 12.06
Total LCSS (n=73, 79)-3.20 ± 15.64-7.13 ± 11.74

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ramucirumab + Docetaxel—30/94 (31.9%)94/94 (100%)
Placebo + Docetaxel—31/98 (31.6%)98/98 (100%)
Most frequent serious events
Showing 10 of 45
Most frequent serious events
EventRamucirumab + DocetaxelPlacebo + Docetaxel
Febrile neutropeniaBlood and lymphatic system disorders8/946/98
Decreased appetiteMetabolism and nutrition disorders4/941/98
Metastases to meningesNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/944/98
PneumothoraxRespiratory, thoracic and mediastinal disorders3/943/98
Lung infectionInfections and infestations1/943/98
General physical health deteriorationGeneral disorders2/940/98
Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders2/942/98
PneumonitisRespiratory, thoracic and mediastinal disorders2/941/98
SplenomegalyBlood and lymphatic system disorders1/940/98
Anorectal disorderGastrointestinal disorders1/940/98
Most frequent other events
Showing 10 of 68
Most frequent other events
EventRamucirumab + DocetaxelPlacebo + Docetaxel
Neutrophil count decreasedInvestigations73/9469/98
White blood cell count decreasedInvestigations73/9468/98
AlopeciaSkin and subcutaneous tissue disorders63/9461/98
Decreased appetiteMetabolism and nutrition disorders54/9451/98
StomatitisGastrointestinal disorders50/9431/98
EpistaxisRespiratory, thoracic and mediastinal disorders46/9418/98
MalaiseGeneral disorders43/9447/98
AnaemiaBlood and lymphatic system disorders37/9441/98
NauseaGastrointestinal disorders34/9439/98
Oedema peripheralGeneral disorders34/9428/98

Baseline characteristics

All randomized participants who had received at least one dose of study drug.

Age, Continuous
Age, Continuous(Years)Ramucirumab + DocetaxelPlacebo + DocetaxelTotal
Median63.9 (29 to 78)64.1 (27 to 79)64 (27 to 79)
Sex: Female, Male
Sex: Female, Male(Participants)Ramucirumab + DocetaxelPlacebo + DocetaxelTotal
Female282755
Male6671137
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ramucirumab + DocetaxelPlacebo + DocetaxelTotal
American Indian or Alaska Native000
Asian9498192
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Ramucirumab + DocetaxelPlacebo + DocetaxelTotal
Japan9498192
08

Study locations

15 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Aichi, 464-8681, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chiba, 277 8577, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ehime, 791-0280, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fukuoka, 830-0011, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hokkaido, 060-8648, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hyogo, 673-8558, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ishikawa, 920-8641, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kanagawa, 236-0051, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Miyagi, 980-8574, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Okayama, 700-8558, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Osaka, 589-8511, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Saitama, 362-0806, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Shizuoka, 411-8777, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tokyo, 135-8550, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Yamaguchi, 755-0241, Japan
09

References and documents

Publications

  • Mitani S, Chen Y, Inoue K, Mori J, Gao L, Long A, Wakabayashi S. Clinical Impact of a Shortened Infusion Duration of Ramucirumab in Japanese Patients -A Model-Based Approach. Gan To Kagaku Ryoho. 2021 Nov;48(11):1381-1387. PubMed 34795131 ↗
  • Yoh K, Hosomi Y, Kasahara K, Yamada K, Takahashi T, Yamamoto N, Nishio M, Ohe Y, Koue T, Nakamura T, Enatsu S, Lee P, Ferry D, Tamura T, Nakagawa K. A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy. Lung Cancer. 2016 Sep;99:186-93. doi: 10.1016/j.lungcan.2016.07.019. Epub 2016 Jul 18. PubMed 27565938 ↗

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2012, a primary completion of Dec 2014 and a completion of Jul 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2016, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2012
First posted
Oct 10, 2012
Start
Dec 2012
Primary completionActual
Dec 2014
CompletionActual
Jul 2016
Results first posted
Jan 20, 2016
Last update
Sep 30, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 30, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01703091
Responsible party
Sponsor
First posted
Oct 10, 2012
Start date
Dec 2012
Primary completion
Dec 2014
Completion
Jul 2016
Results posted
Jan 20, 2016
Last update
Sep 30, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ramucirumab

Start the discussion